| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis Moderate-to-Severe Atopic Dermatitis | Phase 2 | 2026-04-07 |
| Not Yet Recruiting | A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combinatio Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 3 | 2026-03-31 |
| Not Yet Recruiting | Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon C Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer | Phase 3 | 2026-03-15 |
| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis Seasonal Allergic Rhinitis | Phase 2 | 2026-03-02 |
| Not Yet Recruiting | A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases Colorectal Cancer With Hepatic Metastases | Phase 1 / Phase 2 | 2026-03-02 |
| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma Asthma | Phase 2 | 2026-02-28 |
| Recruiting | Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcin Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | Phase 2 | 2025-12-19 |
| Active Not Recruiting | A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects Healthy Male Subjects | Phase 1 | 2025-12-11 |
| Not Yet Recruiting | A Clinical Trial of AK152 in Healthy Volunteers and Patients With Alzheimer' s Disease Alzheimer' s Disease | Phase 1 | 2025-12-01 |
| Recruiting | A Study of Ivonescimab in First-Line ES-SCLC Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | 2025-10-29 |
| Recruiting | A Study of AK138D1 in Advanced Malignant Tumors Solid Cancer | Phase 1 | 2025-10-22 |
| Recruiting | A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer Pancreatic Cancer | Phase 2 | 2025-09-19 |
| Not Yet Recruiting | AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Non-Small Cell Lung Cancer | Phase 2 | 2025-09-05 |
| Recruiting | A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/G Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 3 | 2025-08-14 |
| Recruiting | A Study of AK146D1 for Injection in Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2025-08-07 |
| Not Yet Recruiting | A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Su Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma | Phase 1 | 2025-07-22 |
| Recruiting | A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. Hepatocellular Carcinoma (HCC) | Phase 2 | 2025-07-18 |
| Recruiting | Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer | Phase 3 | 2025-07-08 |
| Recruiting | A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2025-07-02 |
| Not Yet Recruiting | A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Healthy Male Chinese Subjects Healthy Subjects | Phase 1 | 2025-07-01 |
| Not Yet Recruiting | A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC HCC, Hepatocellular Carcinoma | Phase 2 | 2025-06-25 |
| Recruiting | A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have No Small Cell Lung Cancer | Phase 3 | 2025-06-13 |
| Recruiting | A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer Pancreatic Cancer | Phase 3 | 2025-06-11 |
| Recruiting | AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer Colorectal Adenocarcinoma | Phase 3 | 2025-05-27 |
| Recruiting | AK129 Combination Therapy for Advanced Solid Tumors Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma | Phase 1 / Phase 2 | 2025-05-21 |
| Not Yet Recruiting | A Clinical Study of AK139 in Healthy Subjects Healthy Subjects | Phase 1 | 2025-05-06 |
| Recruiting | A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer Biliary Tract Cancer | Phase 1 / Phase 2 | 2025-04-30 |
| Not Yet Recruiting | AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) Chemotherapy-induced Peripheral Neuropathy (CIPN) | Phase 1 | 2025-02-28 |
| Recruiting | A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors Solid Cancer | Phase 1 | 2025-02-24 |
| Recruiting | Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer Platinum-sensitive Ovarian Cancer | Phase 2 | 2025-02-17 |
| Recruiting | AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple Triple-Negative Breast Cancer (TNBC) | Phase 3 | 2025-02-07 |
| Not Yet Recruiting | A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis Atopic Dermatitis | Phase 3 | 2025-01-23 |
| Active Not Recruiting | AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | 2025-01-21 |
| Recruiting | A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma Classic Hodgkin Lymphoma | Phase 1 / Phase 2 | 2025-01-17 |
| Not Yet Recruiting | A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD) Atopic Dermatitis | Phase 2 | 2024-12-30 |
| Not Yet Recruiting | AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors Advanced Malignant Tumors | Phase 1 | 2024-12-01 |
| Recruiting | An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Recurrent Ovarian Cancer | Phase 2 | 2024-11-12 |
| Recruiting | A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC NSCLC (Non-small Cell Lung Cancer) | Phase 3 | 2024-11-12 |
| Not Yet Recruiting | A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects Healthy Subjects (HS) | Phase 1 | 2024-11-04 |
| Recruiting | A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cel Head and Neck Squamous Cell Carcinoma | Phase 3 | 2024-10-30 |
| Active Not Recruiting | AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer Biliary Tract Cancer | Phase 3 | 2024-10-20 |
| Recruiting | A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) Hepatocellular Carcinoma | Phase 1 / Phase 2 | 2024-09-24 |
| Not Yet Recruiting | A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilim Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | 2024-09-10 |
| Recruiting | A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Particip Hepatocellular Carcinoma | Phase 3 | 2024-08-02 |
| Completed | A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis Atopic Dermatitis | Phase 2 | 2024-07-08 |
| Recruiting | A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcin Gastric and Gastroesophageal Junction Adenocarcinoma | Phase 3 | 2024-06-19 |
| Recruiting | A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Derm Atopic Dermatitis | Phase 3 | 2024-04-30 |
| Not Yet Recruiting | A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia ACUTE MYELOID LEUKEMIA; AML | Phase 1 / Phase 2 | 2024-04-29 |
| Recruiting | A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes Higher-risk Myelodysplastic Syndromes | Phase 2 | 2024-02-07 |
| Recruiting | A Study of AK131 in Patients With Advanced Solid Tumors Solid Tumor | Phase 1 | 2024-01-10 |
| Not Yet Recruiting | A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 Advanced Malignant Solid Tumor | Phase 1 | 2023-12-12 |
| Completed | A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis Ankylosing Spondylitis | Phase 3 | 2023-11-22 |
| Not Yet Recruiting | A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Locally Advanced or Metastatic NSCLC | Phase 3 | 2023-11-14 |
| Recruiting | Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junc Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2023-11-13 |
| Completed | A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis Atopic Dermatitis | Phase 2 | 2023-11-06 |
| Active Not Recruiting | A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 / Phase 2 | 2023-10-16 |
| Completed | To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis Psoriasis, Skin Diseases | Phase 2 | 2023-09-22 |
| Recruiting | AK104 for Recurrent or Metastatic Vulvar Cancer Vulvar Cancer | Phase 2 | 2023-08-25 |
| Active Not Recruiting | AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer Advanced Squamous Non Small Cell Lung Cancer | Phase 3 | 2023-08-17 |
| Active Not Recruiting | AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer Advanced Non-small-cell Lung Cancer | Phase 1 / Phase 2 | 2023-07-13 |
| Active Not Recruiting | A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma Renal Cell Carcinoma, First-line Treatment | Phase 2 | 2023-07-06 |
| Recruiting | A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 Advanced Malignant Tumors | Phase 1 | 2023-06-29 |
| Recruiting | A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer Pancreatic Cancer | Phase 2 | 2023-05-25 |
| Active Not Recruiting | A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer Colorectal Cancer | Phase 1 / Phase 2 | 2023-05-08 |
| Recruiting | Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors Solid Tumor, Adult | Phase 1 / Phase 2 | 2023-04-14 |
| Completed | A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis Psoriasis, Skin Diseases | Phase 3 | 2023-03-31 |
| Recruiting | A Study of AK129 in Patients With Advanced Malignant Tumors Advanced Malignant Tumors(Stage IA-IB) | Phase 1 | 2023-03-02 |
| Completed | AK104 in Neoadjuvant Treatment of Cervical Cancer Cervical Cancer | Phase 2 | 2023-02-10 |
| Terminated | Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients NSCLC | Phase 1 / Phase 2 | 2023-02-10 |
| Completed | A Study of AK130 in Patients With Advanced Malignant Tumors Advanced Malignant Tumors | Phase 1 | 2023-02-09 |
| Recruiting | A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection Hepatocellular Carcinoma | Phase 3 | 2023-01-05 |
| Terminated | Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors Solid Tumor, Adult | Phase 1 / Phase 2 | 2022-12-15 |
| Active Not Recruiting | AK112 in Advanced Non-Small Cell Lung Cancer Advanced Non-small-cell Lung Cancer | Phase 3 | 2022-11-09 |
| Completed | A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects Healthy Male Subjects | Phase 1 | 2022-10-25 |
| Completed | A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer SCLC,Extensive Stage | Phase 1 / Phase 2 | 2022-08-26 |
| Completed | A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Hepatocellular Carcinoma | Phase 2 | 2022-08-03 |
| Unknown | A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumor Advanced Malignant Tumors | Phase 1 / Phase 2 | 2022-07-12 |
| Active Not Recruiting | A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC Unresectable, Non-metastatic Hepatocellular Carcinoma | Phase 2 | 2022-06-28 |
| Active Not Recruiting | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer Metastatic Colorectal Cancer | Phase 2 | 2022-06-27 |
| Active Not Recruiting | A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer Locally Advanced Cervical Carcinoma | Phase 3 | 2022-06-21 |
| Unknown | A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2022-06-01 |
| Active Not Recruiting | A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors Advanced Malignant Tumors | Phase 1 / Phase 2 | 2022-05-04 |
| Completed | Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoria Plaque Psoriasis | Phase 3 | 2022-04-08 |
| Active Not Recruiting | A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer | Phase 2 | 2022-03-23 |
| Completed | A Clinical Study of AK115 in Healthy Subjects Healthy Volunteers | Phase 1 | 2022-03-18 |
| Unknown | A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114 Advanced or Metastatic Solid Tumors, Malignancy, Metastasis | Phase 1 | 2022-03-15 |
| Active Not Recruiting | A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer Advanced Non-small Cell Lung Cancer | Phase 2 | 2022-03-09 |
| Active Not Recruiting | AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC Resectable Non-small Cell Lung Cancer | Phase 2 | 2022-02-20 |
| Unknown | A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical H Hodgkin Disease Lymphoma | Phase 3 | 2022-02-15 |
| Terminated | A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asth Asthma | Phase 2 | 2022-02-11 |
| Completed | A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia Hyperlipidemia | Phase 3 | 2022-01-26 |
| Active Not Recruiting | Phase 3 Clinical Study of AK112 for NSCLC Patients Non-Squamous Non-small Cell Lung Cancer | Phase 3 | 2022-01-25 |
| Completed | A Study of AK112 in Advanced Malignant Tumors Advanced Malignant Tumors | Phase 1 / Phase 2 | 2022-01-22 |
| Completed | Study of AK119 in Subjects With Advanced Solid Tumors Solid Tumor | Phase 1 | 2021-12-22 |
| Completed | A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis Psoriasis Vulgaris | Phase 3 | 2021-11-29 |
| Completed | A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia Hyperlipidemia | Phase 3 | 2021-11-04 |
| Completed | A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis Atopic Dermatitis | Phase 1 / Phase 2 | 2021-11-03 |
| Recruiting | A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 / Phase 2 | 2021-11-03 |
| Completed | A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia Hyperlipidemia | Phase 3 | 2021-11-03 |
| Completed | A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcino Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | 2021-09-17 |
| Active Not Recruiting | A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Rec Cervical Cancer | Phase 3 | 2021-08-27 |
| Recruiting | A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | 2021-08-23 |
| Active Not Recruiting | A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | Phase 3 | 2021-08-16 |
| Active Not Recruiting | A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2021-08-13 |
| Terminated | A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer Ovarian Neoplasms, Recurrent Ovarian Carcinoma, Relapsed Ovarian Cancer | Phase 1 / Phase 2 | 2021-06-24 |
| Active Not Recruiting | A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome Myelodysplastic Syndrome | Phase 1 / Phase 2 | 2021-06-18 |
| Completed | A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis Ankylosing Spondylitis | Phase 2 | 2021-06-02 |
| Completed | A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2021-05-21 |
| Completed | A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis Psoriasis | Phase 2 | 2021-04-28 |
| Completed | Study of AK112 in the Treatment of Advanced Gynecological Tumors Gynecologic Cancer, Cancer Metastatic, Ovarian Neoplasms | Phase 2 | 2021-04-09 |
| Completed | A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer Recurrent or Metastatic Cervical Cancer | Phase 2 | 2021-04-01 |
| Completed | Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC SCLC, Extensive Stage | Phase 1 | 2021-03-29 |
| Completed | A Phase 1 Dose Escalation and Expansion Study of AK117 Neoplasms Malignant | Phase 1 | 2021-03-23 |
| Completed | A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | Phase 2 | 2021-02-25 |
| Active Not Recruiting | A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC NSCLC | Phase 2 | 2021-02-01 |
| Completed | A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellula Hepatocellular Carcinoma | Phase 2 | 2021-01-27 |
| Completed | A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors Advanced or Metastatic Solid Tumors | Phase 1 | 2020-12-07 |
| Completed | A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis Ulcerative Colitis | Phase 1 | 2020-11-26 |
| Completed | A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV | Phase 1 / Phase 2 | 2020-11-24 |
| Completed | A Trial of AK104 Plus Anlotinib in NSCLC NSCLC | Phase 1 / Phase 2 | 2020-11-18 |
| Completed | A Study of AK112 for Advanced Solid Tumors Solid Tumor, Adult | Phase 1 / Phase 2 | 2020-10-21 |
| Completed | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer Recurrent Cervical Cancer, Metastatic Cervical Cancer | Phase 2 | 2020-07-15 |
| Completed | A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma Hepatocellular Carcinoma | Phase 1 / Phase 2 | 2020-07-07 |
| Completed | A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors Solid Tumor | Phase 1 | 2020-06-06 |
| Completed | A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis Psoriasis | Phase 1 | 2020-05-28 |
| Terminated | A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | 2020-05-15 |
| Completed | A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia Hypercholesterolemia | Phase 2 | 2020-05-13 |
| Completed | A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | Phase 2 | 2020-04-26 |
| Terminated | A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors MSI-H/dMMR Solid Tumor | Phase 2 | 2020-04-24 |
| Completed | Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors Advanced Solid Tumors, Melanoma | Phase 1 / Phase 2 | 2019-12-20 |
| Completed | Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis Plaque Psoriasis | Phase 2 | 2019-12-19 |
| Completed | A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Heterozygous Familial Hypercholesterolemia | Phase 2 | 2019-11-18 |
| Completed | A Long-term Study of AK102 in Patients With Hypercholesterolemia Hypercholesterolemia | Phase 2 | 2019-11-04 |
| Completed | A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Sol Solid Tumor, Lung Cancer, HCC | Phase 1 / Phase 2 | 2019-09-10 |
| Completed | A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH Homozygous Familial Hypercholesterolemia | Phase 2 | 2019-05-13 |
| Completed | A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | Phase 2 | 2019-03-27 |
| Completed | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-l Gastric Adenocarcinoma, Advanced Solid Tumors, Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | 2019-01-18 |
| Completed | A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer Lung Cancer Non-small Cell Stage IV, Squamous Cell Lung Cancer | Phase 3 | 2018-12-20 |
| Terminated | A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer Lung Cancer Non-small Cell Stage IV | Phase 3 | 2018-11-27 |
| Completed | A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) Hepatocellular Carcinoma | Phase 2 | 2018-11-22 |
| Completed | A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma Hodgkin's Lymphoma | Phase 1 / Phase 2 | 2018-08-13 |
| Completed | A Study of PCSK9 Inhibitor AK102 in Healthy Subjects Hypercholesterolaemia | Phase 1 | 2018-05-23 |
| Completed | A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis Plaque Psoriasis | Phase 1 / Phase 2 | 2018-01-09 |